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Part 1.  Product Information
a) Title: CODEINE-CONTAINING ANALGESICS
b) Product Name/Type: Codeine-Containing Analgesics - MIMS
c) Reference: MIMS Publication July 2005
d) Prescription Required: No
Part 2.  Problem/Issue
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a) Problem/Issue: Further to a previous article about codeine-containing medicinal 
products (March 2004) and recent publicity regarding possible 
inappropriate use, the Irish Medicines Board wishes to again highlight 
among healthcare professionals the importance of discussing use of all 
medications (including non-prescribed medicinal products) with 
patients/consumers. In addition, patients should be advised about the 
need to strictly adhere to the recommended dosage and duration of 
use and to avoid chronic use, which is associated with dependence.   
Health care professionals are also reminded of the following:   Use of 
codeine is contra-indicated in patients with respiratory depression.   
Opioid analgesics such as codeine should be given with care to 
patients receiving tricyclic antidepressants or monamine oxidase 
inhibitors. The effect of CNS depressants (including alcohol) may be 
potentiated by codeine.   Codeine can produce typical opioid effects 
including constipation, nausea, vomiting, dizziness, lightheadedness, 
confusion, drowsiness and urinary retention. The frequency and 
severity are determined by dosage, duration of treatment and individual 
sensitivity.   Codeine is a narcotic analgesic and no more than the 
recommended dose should be taken in any 24-hr period. Consumption 
of quantities in excess of the recommended dose, or for a prolonged 
period of time, may lead to tolerance, psychological and physical 
dependence and may result in symptoms such as restlessness and 
irritability upon cessation of this medicine.   Since 1981, the IMB has 
received a total of eight Adverse Drug Reaction (ADR) reports of 
dependence associated with use of codeine-containing medicinal 
products, all of which arose with prolonged use and/or doses 
exceeding those recommended. The volume of these spontaneous 
ADR reports and available literature reviews suggest the overall 
number of reports of misuse is small, compared with the volume of 
sales of the products. However, recent information has highlighted 
anecdotal concerns raised from some areas around the country, which 
appear from the currently available information to have mainly arisen in 
the context of multiple drug abuse. To ensure a complete and 
comprehensive overview of the national experience of this issue is 
available for review and evaluation, the IMB requests healthcare 
professionals to notify any suspected cases of 
tolerance/dependence/addiction as soon as possible, in the usual way.   
This issue is scheduled for consideration by the IMB’s Expert Sub-
committee of the Advisory Committee for Human Medicines shortly and 
any further advice/recommendations from the Committee will be issued 
following this review.   A downloadable version of the ADR report form 
is available from the IMB’s website (www.imb.ie).  Downloaded forms 
may be completed and sent by freepost to the IMB.  Envelopes should 
be marked “Freepost”,  Pharmacovigilance Unit,  Irish Medicines 
Board, T he Earlsfort Centre,  Earlsfort Terrace,  Dublin 2.   
Alternatively completed forms may be submitted by fax (01-6762517).  
Post-paid report cards are also available from the Pharmacovigilance 
Unit at the IMB (01-6764971).
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